Roche Holding stock broadens Alzheimer's pipeline before CTAD
Published on 11/13/2026 at 18:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRoche's Alzheimer pipeline expands
- Roche is launching the Phase II TARBELA-AD study of investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease.
- The CTAD program includes updated trontinemab findings, PrevenTRON study details and blood-test research.
- Roche will present its portfolio at the Boston congress from November 16 through November 19.
Roche is broadening its Alzheimer's research strategy with the Phase II TARBELA-AD study of RG6434, an investigational oral NLRP3 inhibitor aimed at neuroinflammation. The program was announced on November 10, and Roche will present related research at the Clinical Trials on Alzheimer's Disease Congress in Boston from November 16 through November 19, according to the company's CTAD 2026 release.
Roche Holding stock traded at 434.73 euros on Lang & Schwarz at 18:05 CET on Friday, November 13, 2026. That was 1.35 percent below the 440.70-euro quote cited in the company's previous report on Thursday, November 12.
New approach targets neuroinflammation
TARBELA-AD will evaluate RG6434 in people with early symptomatic Alzheimer's disease. Roche describes the study as randomized, double-blind and placebo-controlled, with efficacy and safety assessment alongside the company's work on amyloid biology.
The company plans to present early Phase I safety data for RG6434 and the rationale and design of TARBELA-AD. Roche's Chief Medical Officer and Head of Global Product Development, Levi Garraway, said the program is intended to test a complementary therapeutic hypothesis rather than replace the group's trontinemab work.
CTAD sets the next milestones
Roche plans 16 accepted abstracts, including updated Phase Ib/IIa Brainshuttle AD findings for trontinemab covering amyloid removal dynamics, biomarkers and safety. The company will also outline its Phase III PrevenTRON study in preclinical Alzheimer's disease, which has started enrolling participants.
The diagnostics program includes clinical, health-economic and real-world research on Elecsys pTau217 and pTau181 blood tests. Roche says Elecsys pTau217 is an FDA-cleared single-biomarker blood test that can both rule in and rule out amyloid pathology.
The Swiss market context is available through current SMI market coverage.
More news and analyses on Roche Holding stock will follow the company's clinical and diagnostic developments.
Roche Holding at a glance
- Company: Roche Holding
- ISIN: CH1499059983
- Trading venue: Lang & Schwarz
- Price: 434.73 euros at 18:05 CET on November 13, 2026
- Change since the November 12 report: down 1.35 percent from 440.70 euros
